Risk stratification and treatment effect of statins in secondary cardiovascular prevention in old age: Additive value of N-terminal pro-B-type natriuretic peptide

European Journal of Preventive Cardiology

Volumn 23, Issue 10, 2016, Pages 1104-1113

  Poortvliet, Rosalinde K E ^a   Van Peet, Petra G ^a   De Craen, Anton J M ^a   Mertens, Bart J A ^a   Mooijaart, Simon P ^a,b,c   Wijsman, Liselotte W ^a,b   Drewes, Yvonne M ^a   Ford, Ian ^d   Sattar, Naveed ^e   Jukema, J Wouter ^a   Stott, David J ^d   De Ruijter, Wouter ^a   Gussekloo, Jacobijn ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Consortium for Healthy Ageing   (Netherlands)

^c Institute for Evidence Based Medicine in Old Age   (Netherlands)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Aged; cardiovascular disease; hydroxymethylglutaryl CoA reductase inhibitors; pro brain natriuretic peptide; risk factors; secondary prevention

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; PRAVASTATIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; SENESCENCE; TREATMENT OUTCOME; VERY ELDERLY; AGE; BLOOD; NETHERLANDS; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SECONDARY PREVENTION;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NATRIURETIC PEPTIDE, BRAIN; NETHERLANDS; PEPTIDE FRAGMENTS; PRAVASTATIN; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION;

EID: 84974593830     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315617908     Document Type: Article

References (36)

1. National Guideline Clearinghouse. European guidelines on cardiovascular disease prevention in clinical practice (version 2012), http://www.guideline.gov/content.aspx?f=rss&id=39354 (2012, accessed 14 July 2014).
2. National Guideline Clearinghouse. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, http://www.guideline.gov/content.aspx?id=39380 (2012, accessed 14 July 2014).
3. National Guideline Clearinghouse. Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines, http://www.guideline.gov/content.aspx?f=rss&id=35273 (2012, accessed 14 July 2014).
4. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: A hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008; 51: 37-45.
5. Koopman C, Vaartjes I, Heintjes EM, et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. Eur Heart J 2013; 34: 3198-3205.
6. Ko DT, Mamdani M, Alter DA,. Lipid-lowering therapy with statins in high-risk elderlypatients: The treatment-risk paradox. JAMA 2004; 291: 1864-1870.
7. Uthoff H, Staub D, Socrates T, et al. PROCAM-, FRAMINGHAM-, SCORE- and SMART-risk score for predicting cardiovascular morbidity and mortality in patients with overt atherosclerosis. Vasa 2010; 39: 325-333.
8. van Peet PG, Drewes YM, de Craen AJ, et al. NT-proBNP best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: The Leiden 85-plus Study. PLoS One 2013; 8: e81400-e81400.
9. Thompson DD, Murray GD, Dennis M, et al. Formal and informal prediction of recurrent stroke and myocardial infarction after stroke: A systematic review and evaluation of clinical prediction models in a new cohort. BMC Med 2014; 12: 58-58.
10. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: Prospective multinational observational study (GRACE). BMJ 2006; 333: 1091-1091.
11. Lafitte M, Pucheu Y, Latry K, et al. Predictors of cardiovascular prognosis in patients receiving optimized secondary prevention measures after acute coronary syndrome. Eur J Prev Cardiol 2013; 20: 283-290.
12. Riedel M, Lafitte M, Pucheu Y, et al. Prognostic value of high-sensitivity C-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment. Eur J Prev Cardiol 2012; 19: 1128-1137.
13. Dorresteijn JA, Visseren FL, Wassink AM, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: The SMART risk score. Heart 2013; 99: 866-872.
14. Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: Systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177-2187.
15. van Peet PG, de Craen AJ, Gussekloo J, et al. Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: The Leiden 85-plus study. Age (Dordr) 2014; 36: 9660-9660.
16. Wannamethee SG, Welsh P, Lowe GD, et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 2011; 58: 56-64.
17. Vaes B, de Ruijter W, Degryse J, et al. Clinical relevance of a raised plasma N-terminal pro-brain natriuretic peptide level in a population-based cohort of nonagenarians. J Am Geriatr Soc 2009; 57: 823-829.
18. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-1630.
19. Ford I, Blauw GJ, Murphy MB, et al. A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening experience and baseline characteristics. Curr Control Trials Cardiovasc Med 2002; 3: 8-8.
20. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999; 84: 1192-1197.
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
22. Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115: 981-989.
23. Cox DR,. Two further applications of a model for binary regression. Biometrika 1958; 45: 562-565.
24. Van Houwelingen JC, Le Cessie S,. Predictive value of statistical models. Stat Med 1990; 9: 1303-1325.
25. Pencina MJ, d'Agostino RB, Vasan RS,. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010; 48: 1703-1711.
26. Pencina MJ, D'Agostino RB Sr, Steyerberg EW,. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
27. Daniels LB, Barrett-Connor E,. Can natriuretic peptides help identify heart failure patients for whom statins are beneficial? J Am Coll Cardiol 2009; 54: 1860-1861.
28. Drewes YM, Poortvliet RK, Blom JW, et al. Homocysteine levels and treatment effect in the prospective study of pravastatin in the elderly at risk. J Am Geriatr Soc 2014; 62: 213-221.
29. Don-Wauchope AC, Santaguida PL, Oremus M, et al. Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: A systematic review. Heart Fail Rev 2014; 19: 521-540.
30. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
31. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114: 201-208.
32. Olsen MH, Hansen TW, Christensen MK, et al. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J Hypertens 2008; 26: 26-34.
33. Wannamethee SG, Welsh P, Lowe GD, et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 2011; 58: 56-64.
34. Patton KK, Ellinor PT, Heckbert SR, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: The Cardiovascular Health Study. Circulation 2009; 120: 1768-1774.
35. Welsh P, Doolin O, Willeit P, et al. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: Results from 15-year follow-up of WOSCOPS. Eur Heart J 2013; 34: 443-450.
36. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: Population based observational cohort study. BMJ 2009; 338: a3083-a3083.